... overload on the mobilization of peripheral blood stem cells (PBSCs) in pediatric patients with β-thalassemia major (TM). Methods: We retrospectively reviewed the records of 226 patients with TM from whom PBSCs were collected. Iron overload was based on serum ferritin level, and liver and cardiac iron...

... the confines of the bones. Since the initiation of regular transfusion programs from an early age for all thalassemia major (ΤΜ) patients, EMH has not been considered a clinical issue anymore. The present study aims to record the prevalence of EMH in chronically transfused ΤΜ patients followed at our...

...Joanne Yacobovich; Hannah Tamary The increased longevity of patients with thalassemia and sickle cell disease (SCD) introduces new clinical challenges due to the accumulation of disease-related morbidity, psychosocial issues and health care adjustments. Patients with thalassemia major now live...

...R. Galanello; S. Campus Iron overload is one of the major causes of morbidity in patients with thalassemia major. Deferiprone (DFP), an orally active iron chelator, emerged from an extensive search for new drugs to treat iron overload. Comparative studies have shown that at comparable doses...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Hearing defect Iron overload Thalassemia major Serum ferritin Acta haemat. 61: 209-215 (1979) Auditory Involvement...

...E. Silvestroni; I. Bianco; B. Graziani; M. Lerone; M. Valente; P. Congedo; D. Ponzini; S. Costantini Subcutaneous infusions of Desferal (DF) rarely induce negative iron balance in thalassemia major patients less than 6 years old. In nonsplenectomized patients the requirements for blood transfusions...

...F. Schettini; A. Mautone; L. Cavallo; M. Altomare; O. Montagna; L. Dell’Edera A longitudinal study has been conducted on serum ferritin concentrations in children with thalassemia major treated with desferrioxamine (DFO), both intramuscularly and by continuous subcutaneous infusion, in order...

...S. de Virgiliis; P. Cossu; G. Sanna; F. Frau; E. Loi; R. Lobrano; A. Nucaro; C. Toccafondi; G. Cornacchia; A. Loi; A. Cao In this study maximum urinary iron elimination with continuous desferrioxamine subcutaneous infusion was obtained in thalassemia major patients with chronic persistent or active...

...Salvatore Musumeci; Salvatore Leonardi; Riccardo Di Dio; Alberto Fischer; Giuseppina Di Costa Seventy-four patients with β- thalassemia major were studied to test the hypothesis that a deficiency of protein C (PC) and antithrombin III (AT III), both antithrombotic proteins, could contribute...

...F. Argiolu; G. Diana; M. Arnone; M.G. Batzella; P. Piras; A. Cao Patients with thalassemia major due to red blood cell autoantibodies may develop an increase in transfusional blood consumption. In this study we report the results of treatment with high intravenous immunoglobulin (Ig) in 4 patients...

...Vincenzo De Satictis; Calogero Vullo; Bruno Bagni; Loretta Chiccoli In the last 18 years, we have observed 24 cases of hypoparathyroidism (HPT) in β-thalassemia major. At present, 4.5% of patients followed regularly in our department have this complication. HPT is thought to be mainly...

...N.S. Smetanina; L.-H. Gu; G. Schilirò; A. Di Cataldo; R. Testa; Z. Jakovlevska; G.D. Efremov; T.H.J. Huisman We have determined the relative quantities of γ- and β-mRNAs and the α/β-mRNA ratios in 37 patients with β-thalassemia major with specific genotypes, namely 8 with a homozygosity for codon...

..., Italy Key Words NK cells Lymphocyte subsets Thalassemia major Hepatitis C Alpha-interferon Original Paper Acta Haematol 1997;98:83-88 Received: March 14,1996 Accepted: November 25,1996 Effect of Alpha-Interferon on Natural Killer Cell Activity and Lymphocyte Subsets in Thalassemia Patients with Chronic...

...-thalassemia major patients. r-Hu-EPO (Eprex/Cilag, Switzerland) was given to the patients at an initial dose of 500 IU/kg s.c. 3 times a week for at least 2 months during which no transfusion was applied. A sustained hemoglobin (Hb) level greater than 8 g/dl was considered as a response to EPO treatment...

... was to determine the safety of long-term therapy with high-dose (100 mg/kg/day) deferiprone. A secondary aim was to determine the efficacy of this high dose. Twelve thalassemia major patients received deferiprone at a dose of100 mg/kg/day over 2 years. Transient aspartate aminotransferase increase (8 patients...

... this. References 1. Jessup M, Manno CS: Diagnosis and management of iron induced heart disease in Cooley’s anemia. Ann NY Acad Sci 1998;850/1:242–250. 2. Zurlo MG, DeStefano P, Borgna-Pignatti C: Survival and causes of death in thalassemia major. Lancet 1989;ii:27–30. 3. Modell B, Khan M, Darlison M...

...G.C. Ooi; P.L. Khong; W.K. Lam; N.J. Trendell-Smith; K.W.T. Tsang Lung function abnormalities that are associated with thalassemia major are variable with etiology that is yet undetermined. Some studies have suggested that pulmonary iron deposition is a probable cause for these lung defects...

...J. Jaime Caro; Alexandra Ward; Traci Craig Green; Krista Huybrechts; Alejandro Arana; Suzanne Wait; Androulla Eleftheriou Objective: To describe the burden of thalassemia major and its treatment, in terms of prevalence of iron-overload-related complications, direct and indirect costs...